Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Necrolytic migratory erythma (NME) is an obligatory paraneoplastic syndrome. Here we describe a woman admitted to the dermatology ward with NME which was later found to be associated with glucagonoma, a slow-growing, rare pancreatic neuroendocrine tumor. Even more rarely, the tumor was located in the pancreas head, while most of such lesions are located in the distal pancreas. The diagnosis of this rare tumor requires an elevated serum glucagon level and imaging confirming a pancreatic tumor. After surgical removal of the tumor, the patient's cutaneous and systemic features resolved. It is therefore imperative that clinicians recognize NME early in order to make an accurate diagnosis and to provide treatment for this rare tumor.

Original languageEnglish
Article number220
JournalWorld Journal of Surgical Oncology
Volume12
Issue number1
DOIs
StatePublished - 17 Jul 2014
Externally publishedYes

Keywords

  • Glucagonoma
  • Necrolytic migratory erythema
  • Pancreatic neuroendocrine tumors

Fingerprint

Dive into the research topics of 'Necrolytic migratory erythema as the first manifestation of pancreatic neuroendocrine tumor'. Together they form a unique fingerprint.

Cite this